Clinical Trial Update: A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the bioavailability of pembrolizumab when given via subcutaneous injection with berahyaluronidase alfa in patients with advanced solid …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Berahyaluronidase Alfa (berahyaluronidase alfa)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Advanced or Metastatic Solid Tumors | Phase 1 | Status: ACTIVE_NOT_RECRUITING